CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis

Chest

Volumn 153, Issue 2, 2018, Pages 339-348

  Glasgow, Connie G ^a   Pacheco Rodriguez, Gustavo ^a   Steagall, Wendy K ^a   Haughey, Mary E ^a   Julien Williams, Patricia A ^a   Stylianou, Mario P ^a   Gochuico, Bernadette R ^b   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

CA 125; lymphangioleiomyomatosis; mTOR; pleural effusion; tuberous sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CA 125 ANTIGEN; RAPAMYCIN; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG DISEASE; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; PLEURA EFFUSION; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANALYSIS OF VARIANCE; BLOOD; DISEASE EXACERBATION; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOMARKERS; CA-125 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; PLEURAL EFFUSION; RESPIRATORY FUNCTION TESTS; SIROLIMUS; YOUNG ADULT;

EID: 85041913932     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.05.018     Document Type: Article

References (44)

1. Taveira-DaSilva, A.M., Moss, J., Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 7 (2015), 249–257.
2. Glasgow, C.G., Steagall, W.K., Taveira-Dasilva, A., et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 104:suppl 1 (2010), S45–S58.
3. Laplante, M., Sabatini, D.M., mTOR signaling in growth control and disease. Cell 149:2 (2012), 274–293.
4. Goncharova, E.A., Goncharov, D.A., Spaits, M., et al. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 34:5 (2006), 561–572.
5. Benjamin, D., Colombi, M., Moroni, C., Hall, M.N., Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10:11 (2011), 868–880.
6. McCormack, F.X., Inoue, Y., Moss, J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:17 (2011), 1595–1606.
7. Bissler, J.J., McCormack, F.X., Young, L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:2 (2008), 140–151.
8. Taveira-DaSilva, A.M., Hathaway, O., Stylianou, M., Moss, J., Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 154:12 (2011), 797–805.
9. Moua, T., Olson, E.J., St. Jean, H.C., Ryu, J.H., Resolution of chylous pulmonary congestion and respiratory failure in LAM with sirolimus therapy. Am J Respir Crit Care Med 186:4 (2012), 389–390.
10. Bast, R.C. Jr., Feeney, M., Lazarus, H., Nadler, L.M., Colvin, R.B., Knapp, R.C., Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:5 (1981), 1331–1337.
11. Haridas, D., Ponnusamy, M.P., Chugh, S., Lakshmanan, I., Seshacharyulu, P., Batra, S.K., MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J 28:10 (2014), 4183–4199.
12. Gipson, I.K., Blalock, T., Tisdale, A., et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod 78:1 (2008), 134–142.
13. Rachagani, S., Torres, M.P., Moniaux, N., Batra, S.K., Current status of mucins in the diagnosis and therapy of cancer. Biofactors 35:6 (2009), 509–527.
14. Blalock, T.D., Spurr-Michaud, S.J., Tisdale, A.S., et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 48:10 (2007), 4509–4518.
15. Kesimer, M., Scull, M., Brighton, B., et al. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J 23:6 (2009), 1858–1868.
16. Gadducci, A., Cosio, S., Fanucchi, A., Negri, S., Cristofani, R., Genazzani, A.R., The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 93:1 (2004), 131–136.
17. Zhang, S.J., Hu, Y., Qian, H.L., et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev 14:6 (2013), 3937–3940.
18. Cedres, S., Nunez, I., Longo, M., et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 12:3 (2011), 172–179.
19. Patsner, B., Yim, G.W., Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: the Asian experience 2000 to 2012. Obstet Gynecol Sci 56:5 (2013), 281–288.
20. Polat, E., Duman, U., Duman, M., et al. Preoperative serum tumor marker levels in gastric cancer. Pak J Med Sci 30:1 (2014), 145–149.
21. Taveira-DaSilva, A.M., Stylianou, M.P., Hedin, C.J., Hathaway, O., Moss, J., Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126:6 (2004), 1867–1874.
22. Steagall, W.K., Pacheco-Rodriguez, G., Glasgow, C.G., et al. Osteoprotegerin contributes to the metastatic potential of cells with dysfunctional TSC2 tumor suppressor gene. Am J Pathol 183:3 (2013), 938–950.
23. Young, L.R., VanDyke, R., Gulleman, P.M., et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138:3 (2010), 674–681.
24. Young, L.R., Lee, H.S., Inoue, Y., et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 1:6 (2013), 445–452.
25. Matsumoto, Y., Horiba, K., Usuki, J., Chu, S.C., Ferrans, V.J., Moss, J., Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 21:3 (1999), 327–336.
26. Nouwen, E.J., Pollet, D.E., Eerdekens, M.W., Hendrix, P.G., Briers, T.W., De Broe, M.E., Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen, and cancer antigen 125 in normal and neoplastic human lung. Cancer Res 46:2 (1986), 866–876.
27. Valencia, J.C., Steagall, W.K., Zhang, Y., et al. Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules. Chest 147:3 (2015), 771–777.
28. Felder, M., Kapur, A., Gonzalez-Bosquet, J., et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Molecular Cancer 13 (2014), 129–143.
29. Prizant, H., Taya, M., Lerman, I., et al. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model. Endocr Relat Cancer 23:4 (2016), 265–280.
30. Barnes, E.A., Kenerson, H.L., Mak, B.C., Yeung, R.S., The loss of tuberin promotes cell invasion through the β-catenin pathway. Am J Respir Cell Mol Biol 43:5 (2010), 617–627.
31. Hayashi, T., Fleming, M.V., Stetler-Stevenson, W.G., et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 28:9 (1997), 1071–1078.
32. Rump, A., Morikawa, Y., Tanaka, M., et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:10 (2004), 9190–9198.
33. Chen, S.H., Hung, W.C., Wang, P., Paul, C., Konstantopoulos, K., Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep, 3, 2013, 1870.
34. Seelenmeyer, C., Wegehingel, S., Lechner, J., Nickel, W., The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 116:pt 7 (2003), 1305–1318.
35. White, N.M., Masui, O., Newsted, D., et al. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer 110:5 (2014), 1250–1259.
36. Bottoni, P., Scatena, R., The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 867 (2015), 229–244.
37. Sevinc, A., Buyukberber, S., Ramazan, S., Kiroglu, Y., Turk, H.M., Ates, M., Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 77:2 (2000), 254–257.
38. Lindgren, J., Kuusela, P., Hellstrom, P.E., Pettersson, T., Klockars, M., The ovarian cancer associated antigen CA 125 in patients with pleural effusions. Eur J Cancer Clin Oncol 24:4 (1988), 737–739.
39. Bergmann, J.F., Bidart, J.M., George, M., Beaugrand, M., Levy, V.G., Bohuon, C., Elevation of CA 125 in patients with benign and malignant ascites. Cancer 59:2 (1987), 213–217.
40. Hazarika, N., Dhabhar, B., Saikia, T.K., Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass—a diagnostic dilemma. JAPI 56 (2008), 47–48.
41. Mak, G.Z., Welsh, J.H., Chang, E., Lathi, R.B., Poythress, E.L., Chylous ascites caused by sarcoidosis. Hospital Physician, 38(1), 2002 27-32,36.
42. Zuckerman, E., Lanir, A., Sabo, E., et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 94:6 (1999), 1613–1618.
43. Ando, K., Kurihara, M., Kataoka, H., et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig 51:3 (2013), 175–183.
44. Glasgow, C.G., Avila, N.A., Lin, J.P., Stylianou, M.P., Moss, J., Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 135:5 (2009), 1293–1300.